Expression of Gluc in mammalian cells did not itself elicit an ER stress response, but induction of ER stress led to a temporary decrease in Gluc secretion which correlated with an increase in XBP-1 message splicing and levels of phosphorylated eIF2alpha, known ER stress indicators. Also, a fusion protein including Gluc and yellow fluorescence protein allowed visualization of the secretory pathway within cells, as well as serving as a means of monitoring secretion of luciferase activity. The Gluc assay proved to be over 20,000-fold more sensitive in monitoring the secretory pathway in mammalian cells as compared to the SEAP assay in a range covering over 5 orders of magnitude with respect to cell number. In order to assess the linearity of Gluc with respect to time, 293T cells were infected with the lentivirus vector carrying the expression cassette for Gluc. Forty-eight hrs post-infection, fresh medium was added and the level of secreted Gluc was assayed overtime by taking an aliquot of the conditioned medium, adding coelenterazine, and measuring photon counts using a luminometer. The secreted bioluminescent signal of Gluc from cells into the conditioned medium was linear with respect to time over 72 hrs postinfection. This assay will provide a means to identify drugs which can counteract the effects of mutant proteins using high throughput Folic acid screens, and has the potential to monitor effects of these drugs on ER stress in vivo. Human African trypanosomiasis or sleeping sickness, caused by the protozoan parasite Trypanosoma brucei gambiense transmitted by the Tsetse fly, progresses from the hemolymphatic phase to the meningoencephalitic phase. Without appropriate treatment, the disease is invariably fatal. Since 1949, melarsoprol has been the most commonly used stage 2 treatment. This arsenical derivative is associated with severe toxic effects, in particular a reactive encephalopathy that is fatal of cases and affects 5%�C10% of patients treated. An additional concern is the increase of melarsoprol treatment failures reported in several Miglitol countries, up to 30%. E flornithine or DFMO, initially evaluated for the treatment of cancer, has been the only new drug registered in over ?ve decades for HAT.